{
    "organizations": [],
    "uuid": "90c8e8ba37dbcdc391eef0d3875534e268ae3128",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-the-ema-grants-accelerated-assessm/brief-the-ema-grants-accelerated-assessment-for-shires-lanadelumab-idUSFWN1QH19O",
    "ord_in_thread": 0,
    "title": "BRIEF-The EMA Grants Accelerated Assessment For Shire's Lanadelumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Shire Plc:\n* THE EMA GRANTS ACCELERATED ASSESSMENT FOR SHIRE‘S LANADELUMAB BEING EVALUATED FOR THE PREVENTION OF ATTACKS IN HAE PATIENTS AGED 12 YEARS AND OLDER\n* SAYS IS ON TRACK TO SUBMIT EU MARKETING AUTHORIZATION APPLICATION FOR SHP643 IN COMING WEEKS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T00:34:00.000+02:00",
    "crawled": "2018-02-28T13:21:24.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "shire",
        "plc",
        "ema",
        "grant",
        "accelerated",
        "assessment",
        "shire",
        "lanadelumab",
        "evaluated",
        "prevention",
        "attack",
        "hae",
        "patient",
        "aged",
        "year",
        "older",
        "say",
        "track",
        "submit",
        "eu",
        "marketing",
        "authorization",
        "application",
        "shp643",
        "coming",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}